Search results for "ESL"

showing 10 items of 250 documents

Non-existence of unfair delay in the exercise of claim actio for amounts unduly collected. Comment on Spanish STS no. 243/2019, of April (RJ 2019, 15…

2020

El Tribunal Supremo considera que el mero retraso en el ejercicio de una acción de reclamación de cantidad no puede ser considerado por si sólo constitutivo de retraso desleal. Además, es necesario que previamente al ejercicio del derecho existan hechos, actos o conductas que provoquen en el obligado la confianza de que el derecho en su contra no se ejercitará. The Supreme Court considers that the mere delay in the exercise of an action of claim of quantity cannot be considered to constitute unfair delay. In addition, it is necessary that prior to the exercise of the right there are facts, acts or conducts that cause int the obliged the confidence that the right against him will not be exer…

:CIENCIAS JURÍDICAS [UNESCO]VerwirkungUNESCO::CIENCIAS JURÍDICASplazo de prescripciónaction of claim of quantityterm of prescriptionhumanitieshealth care economics and organizationsacción de reclamación de cantidadretraso deslealunfair delay
researchProduct

La obsolescencia programada : un supuesto de práctica comercial desleal con consumidores

2021

El presente artículo analiza la estrategia comercial desarrollada por la empresa multinacional estadounidense Apple basada en la obsolescencia programada de sus ?smartphones? y su posible consideración como práctica comercial desleal con consumidores y usuarios en el sentido de la Directiva 2005/29/CE.

:CIENCIAS JURÍDICAS [UNESCO]prácticas agresivasomisiones engañosasmisleading omissionsplanned obsolescenceconsumersconsumidoresobsolescencia programadaUNESCO::CIENCIAS JURÍDICASUnfair practicesElisabet El presente artículo analiza la estrategia comercial desarrollada por la empresa multinacional estadounidense Apple basada en la obsolescencia programada de sus ?smartphones? y su posible consideración como práctica comercial desleal con consumidores y usuarios en el sentido de la Directiva 2005/29/CE. Prácticas deslealesaggressive practices 466 4812070-8157 22082 Revista Boliviana de Derecho 584568 2021 32 8055228 La obsolescencia programada un supuesto de práctica comercial desleal con consumidores González Pons
researchProduct

Chemical Composition and antimicrobial activity of the essential oils from two species of Thimus growing wild in southern Italy

2009

The volatile constituents of the aerial parts of two samples of Thymus longicaulis C. Presl, collected in Campania and in Sicily, and two samples of Thymus pulegioides L. from the same regions, were extracted by hydrodistillation and analyzed. Considering the four oils together, seventy-eight different compounds were identified: 57 for Thymus longicaulis from Sicily (91.1% of the total oil), 40 for Thymus longicaulis from Campania (91.5% of the oil), 39 for Thymus pulegioides from Sicily (92.5% of the oil) and 29 for Thymus pulegioides from Campania (90.1% of the oil). The composition of the oils is different, although the most abundant components are identical in T. pulegioides. The essent…

<em>Thymus longicaulis</em> C. Presl; <em>Thymus pulegioides </em>L.; essential oil composition; thymol; geraniol; antibacterial activityThymus pulegioidesPharmaceutical ScienceMicrobial Sensitivity TestsArticleAnalytical Chemistrylcsh:QD241-441Thymus Plantchemistry.chemical_compoundlcsh:Organic chemistryantibacterial activitythymolDrug DiscoveryBotanyOils VolatilePlant OilsThymus PlantSettore BIO/15 - Biologia FarmaceuticaPhysical and Theoretical ChemistrygeraniolThymolChemical compositionessential oil compositionThymus longicaulisbiologyBacteriaThymus pulegioides L.Organic ChemistrySettore CHIM/06 - Chimica Organicabiology.organism_classificationAntimicrobialAnti-Bacterial AgentschemistryItalyantimicrobial activity essential oils Thimus longicaulis Thimus pulegioidesChemistry (miscellaneous)Molecular MedicineComposition (visual arts)Thymus longicaulis C. PreslGeraniol
researchProduct

Modulation of adipokines and cytokines in gestational diabetes and macrosomia.

2006

Abstract Context/Objective: Not much is known about the implication of adipokines and different cytokines in gestational diabetes mellitus (GDM) and macrosomia. The purpose of this study was to assess the profile of these hormones and cytokines in macrosomic babies, born to gestational diabetic women. Design/Subjects: A total of 59 women (age, 19–42 yr) suffering from GDM with their macrosomic babies (4.35 ± 0.06 kg) and 60 healthy age-matched pregnant women and their newborns (3.22 ± 0.08 kg) were selected. Methods: Serum adipokines (adiponectin and leptin) were quantified using an obesity-related multiple ELISA microarray kit. The concentrations of serum cytokines were determined by ELISA…

AdultBlood GlucoseLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryAdipokineBiochemistryProinflammatory cytokineFetal MacrosomiaInterferon-gammaEndocrinologyAldesleukinPregnancyInternal medicineDiabetes mellitusFetal macrosomiaMedicineHumansInsulinAdiponectinbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaLeptinBiochemistry (medical)Infant Newbornmedicine.diseaseLipidsGestational diabetesDiabetes GestationalEndocrinologyCytokinesInterleukin-2FemaleAdiponectinInterleukin-4businessThe Journal of clinical endocrinology and metabolism
researchProduct

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…

2004

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…

AdultCyclopropanesMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingSettore MED/09 - Medicina InternaAdolescentUrticariamedicine.medical_treatmentImmunologyPlacebo-controlled studyRandomized placebo-controlled trial; desloratadine; montelukast; chronic idiopathic urticariaAcetatesSulfidesPlaceboGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineImmunology and AllergyHumansMontelukastAgedDesloratadineLeukotriene E4Leukotriene receptorbusiness.industrydesloratadineRandomized placebo-controlled trialLoratadineMiddle AgedAntileukotrieneTreatment OutcomechemistryAnesthesiachronic idiopathic urticariaChronic DiseasemontelukastQuinolinesLeukotriene AntagonistsFemalebusinessmedicine.drug
researchProduct

MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas

2020

Several studies have focused on identifying microRNAs involved in the pathogenesis of melanoma. However, its association with clinicopathological features has been scarcely addressed. The aim of this study is to identify microRNAs expression profiles related to aggressive clinicopathological and molecular features, and to analyze the association with melanoma survival. A retrospective and observational study was performed in a series of 179 formalin-fixed paraffin embedded primary cutaneous melanomas. First, a screening analysis on a discovery set (n = 22) using miRNA gene chip array (Affymetrix, Santa Clara, California, USA) was performed. Differentially expressed microRNAs were detected e…

AdultMale0301 basic medicineCancer ResearchPoor prognosisSkin NeoplasmsTERT mutationsDermatologyBiologyPathogenesisBreslow Thickness03 medical and health sciences0302 clinical medicinemicroRNAmelanomamedicineHumansMelanomaMitosisSurvival analysisAgedMelanomaMicroRNA Expression ProfileMiddle AgedPrognosismedicine.diseasemicroRNAsMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchFemaleprognosisclinicopathological featuresMelanoma Research
researchProduct

Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.

2000

BACKGROUND Making a morphologic distinction between benign and malignant melanocytic tumors of the skin is frequently difficult, especially because “gray zones” between these lesions often exist. DNA image cytometry as an adjuvant method for the diagnosis and prognostic prediction of premalignant lesions and malignant tumors of many other organs is already well established. The aim of this study was to determine whether DNA image cytometry is helpful in distinguishing benign from malignant melanocytic lesions and whether cytometry would give valid information with which to predict the prognoses associated with malignant melanomas. METHODS DNA image cytometry was performed on 127 benign and …

AdultMaleCancer ResearchPathologymedicine.medical_specialtySkin NeoplasmsStatistics as TopicVideo RecordingMalignant transformationBreslow ThicknessHutchinson's Melanotic FreckleNevus BlueNevus Epithelioid and Spindle CellmedicineHumansMelanomaNevusDNA Image CytometryImage CytometryRetrospective StudiesPloidiesbusiness.industryMelanomaCancerReproducibility of ResultsDNA NeoplasmMiddle Agedmedicine.diseaseAneuploidyPrognosisDiploidyHMB-45OncologyEvaluation Studies as TopicImage CytometryMelanocytesFemalebusinessCytometryDysplastic Nevus SyndromePrecancerous ConditionsFollow-Up StudiesForecastingCancer
researchProduct

Primary cutaneous melanoma in hidden sites is associated with thicker tumours — a study of 829 patients

2001

The aim of this study was to determine if primary cutaneous melanomas in hidden anatomical sites were associated with thicker tumours. Retrospective medical data of 829 patients with melanomas diagnosed at our centre between January 1976 and July 1998 were recorded from our database. Three groups were defined according to the anatomical site of the primary melanoma: (1) visible areas (group 1: 493 patients); (2) visible areas only to the patients or to their partners in privacy (group 2: 281 patients); and (3) hidden areas (group 3: 55 patients). Univariate analysis indicated that patients with melanoma in hidden regions presented significantly thicker tumours (median for group 3: 2.25 vers…

AdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsMultivariate analysisAdolescentDiseaseBreslow ThicknessSex FactorsInternal medicinemedicineHumansMelanomaAgedNeoplasm StagingRetrospective StudiesAged 80 and overAnalysis of VarianceUnivariate analysisbusiness.industryMelanomaAge FactorsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryAnatomical sitesOncologyCutaneous melanomaFemalebusinessEuropean Journal of Cancer
researchProduct

Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: Results from a German prospective multicenter clinical pra…

2019

Abstract Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED) approved as monotherapy for partial-onset seizures in adults and as adjunctive therapy in patients aged above 6 years in the European Union (EU). The prospective observational Zebinix Effects in DEpendency of BAseline Conditions (ZEDEBAC) study aimed at investigating the effectiveness of ESL in clinical practice, with ESL being administered as monotherapy (mono group), as only add-on to a current monotherapy (1 + group), or as add-on to ≥ 2 baseline AEDs (≥ 2 + group). In total, 237 patients were included, 35 in the mono group, 114 in the 1 +, and 88 in the ≥ 2 + group. Six-month retention rates were 93.9%…

AdultMaleDrug Resistant Epilepsymedicine.medical_specialtyYoung Adult03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineSodium channel blockerRefractoryDibenzazepinesSeizuresInternal medicineHumansMedicinemedia_common.cataloged_instanceProspective Studies030212 general & internal medicineEuropean unionAgedmedia_commonbusiness.industryMiddle Agedmedicine.diseaseNeurologyEslicarbazepine acetateConcomitantAnticonvulsantsFemaleObservational studyNeurology (clinical)businessHyponatremia030217 neurology & neurosurgerySodium Channel Blockersmedicine.drugEpilepsy &amp; Behavior
researchProduct

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised…

2015

Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations. Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death. We aimed to assess the efficacy and safety of reslizumab in patients with inadequately controlled, moderate-to-severe asthma.We did two duplicate, multicentre, double-blind, parallel-group, randomised, placebo-controlled phase 3 trials. Both trials enrolled patients with asthma aged 12-75 years (from 128 clinical research centres in study 1 and 104 centres in study 2) from Asia, Australia, North America, South America, South Africa, and Europe, whose asthma was inadequately c…

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAsiaAntibodies Monoclonal HumanizedPlaceboLebrikizumablaw.inventionSouth Africachemistry.chemical_compoundDouble-Blind MethodRandomized controlled trialReslizumablawmedicineHumansAsthmaIntention-to-treat analysisbusiness.industryAustraliaMiddle AgedSouth Americamedicine.diseaseBenralizumabAsthmaEosinophilsEuropeClinical trialTreatment OutcomechemistryNorth AmericaFemalebusinessmedicine.drugThe Lancet Respiratory Medicine
researchProduct